Healthcare [ 7/13 ] | Biotechnology [ 82/163 ]
NASDAQ | Common Stock
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process.
Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.
The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation.
In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment.
Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data.
Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications.
The company was incorporated in 2013 and is headquartered in Dallas, Texas.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 9, 24 | -0.51 Decreased by -40.69% | -0.43 Decreased by -17.79% |
| Mar 18, 24 | -0.39 Decreased by -25.81% | -0.40 Increased by +2.50% |
| Nov 8, 23 | -0.29 Decreased by -38.10% | -0.45 Increased by +35.56% |
| Aug 9, 23 | -0.44 Decreased by -7.32% | -0.43 Decreased by -2.33% |
| May 9, 23 | -0.36 Increased by +5.26% | -0.48 Increased by +25.00% |
| Mar 20, 23 | -0.31 Increased by +3.13% | -0.47 Increased by +34.04% |
| Nov 7, 22 | -0.21 Increased by +41.67% | -0.48 Increased by +56.25% |
| Aug 8, 22 | -0.41 Decreased by -95.24% | -0.52 Increased by +21.15% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 0.00 Decreased by N/A% | -5.44 M Decreased by -57.74% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 261.05 K Increased by +N/A% | -4.19 M Decreased by -42.58% | Decreased by -1.60 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -3.16 M Decreased by -32.61% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -4.75 M Decreased by -3.41% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -3.45 M Increased by +17.43% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -2.94 M Increased by +17.07% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -2.38 M Increased by +41.19% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -4.59 M Decreased by -98.14% | Decreased by N/A% Decreased by N/A% |